Mitotic Defects Lead to Neuronal Aneuploidy and Apoptosis in Frontotemporal Lobar Degeneration Caused by MAPT Mutations. by Caneus J et al.
 
 
 
 
 
Newcastle University ePrints | eprint.ncl.ac.uk 
Caneus J, Granic A, Rademakers R, Dickson DW, Coughlan CM, Chial HJ, Potter 
H. Mitotic Defects Lead to Neuronal Aneuploidy and Apoptosis in 
Frontotemporal Lobar Degeneration Caused by MAPT Mutations. Molecular 
Biology of the Cell (2017)
DOI link 
https://doi.org/10.1091/mbc.E17-01-0031  
ePrints link 
http://eprint.ncl.ac.uk/244739  
Date deposited 
27/02/2018 
 
Licence 
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 
3.0 Unported License 
 
 
1 
 
Mitotic Defects Lead to Neuronal Aneuploidy and Apoptosis 
in Frontotemporal Lobar Degeneration Caused by MAPT 
Mutations 
Julbert Caneusa,b*, Antoneta Granica,c,d,e*, Rosa Rademakersf, Dennis W. Dicksonf, 
Christina M. Coughlana, Heidi J. Chiala, and Huntington Pottera,b,† 
 
a Department of Neurology, Rocky Mountain Alzheimer’s Disease Center, and Linda 
Crnic Institute for Down Syndrome, University of Colorado School of Medicine, 12700 E. 
19th Ave. MS8608, Aurora, CO, 80045 USA 
b Neuroscience Program, University of Colorado, Anschutz Medical Campus, Aurora, 
CO 80045 
c AGE Research Group, Institute of Neuroscience, Newcastle University, Newcastle 
upon Tyne, United Kingdom, Campus for Ageing and Vitality, Biomedical Research 
Building, Newcastle University, Newcastle upon Tyne, NE4 5PL 
d NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS 
Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom 
e Newcastle University Institute for Ageing, Newcastle upon Tyne, United Kingdom,  
f Department of Neuroscience, Mayo Clinic, 4500 San Pablo Rd., Jacksonville FL 32224 
 
  
 
 
* These Authors contributed equally to the paper 
† Contact: Huntington Potter, Huntington.Potter@ucdenver.edu (303) 724-7385 
   
Running Head: Aneuploidy and Apoptosis in FTLD-MAPT Neurons 
Abbreviations: frontotemporal lobar degeneration (FTLD), frontotemporal dementia (FTD), 
Alzheimer’s disease (AD)  
2 
 
Abstract 
Mutant Tau (MAPT) can lead to frontotemporal lobar degeneration (FTLD). Previous 
studies associated MAPT mutations and altered function with aneuploidy and 
chromosome instability in human lymphocytes and in Drosophila development. Here, 
we examine whether FTLD-causing mutations in human MAPT induce aneuploidy and 
apoptosis in the mammalian brain. First, aneuploidy was found in brain cells from MAPT 
mutant transgenic mice expressing FTLD mutant human MAPT. Then, brain neurons 
from mice homozygous or heterozygous for the Tau (Mapt) null allele were found to 
exhibit increasing levels of aneuploidy with decreasing Tau gene dosage. To determine 
whether aneuploidy leads to neurodegeneration in FTLD, we measured aneuploidy and 
apoptosis in brain cells from patients with MAPT mutations and identified both increased 
aneuploidy and apoptosis in the same brain neurons and glia. To determine whether 
there is a direct relationship between MAPT-induced aneuploidy and apoptosis, we 
expressed FTLD-causing mutant forms of MAPT in karyotypically normal human cells 
and found that they cause aneuploidy and mitotic spindle defects that then result in 
apoptosis. Collectively, our findings reveal a neurodegenerative pathway in FTLD-
MAPT in which neurons and glia exhibit mitotic spindle abnormalities, chromosome mis-
segregation, and aneuploidy, which then lead to apoptosis. 
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Introduction 
Frontotemporal lobar degeneration (FTLD), also termed frontotemporal dementia (FTD), 
is most often an early-onset neurodegenerative disease in which a subset of cases has 
tau-positive neuronal and glial inclusions in the absence of Alzheimer’s disease (AD)-
like amyloid deposits, whereas other cases have TDP-43 neuronal and glial inclusions 
(Rademakers et al., 2012). Familial forms of FTLD are associated with mutations in 
several genes, and 50-80% of FTLD cases are sporadic. Some autosomal dominant 
familial forms of FTLD and Parkinsonism are linked to chromosome 17 (FTDP-17) and 
are caused by mutations in one of two nearby genes, the tau gene (MAPT) or the 
progranulin gene (PGRN). A large proportion of familial FTLD and of amyotrophic lateral 
sclerosis (ALS) is also caused by abnormal expansions of a hexanucleotide repeat in 
the C9orf72 gene (Rademakers et al., 2012).  
 
A potential mechanism by which FTLD arises in patients with MAPT mutations is 
suggested by work on AD. We previously proposed that trisomy 21 mosaicism may 
underlie the development of AD (Potter, 1991), and subsequent studies demonstrated 
that people with both sporadic and familial forms of AD exhibit trisomy 21 mosaicism 
and other aneuploidy in all tissues examined, including in brain neurons and glia (Potter 
H, 1995; Migliore et al., 1997; Geller and Potter, 1999; Kingsbury et al., 2006; Mosch et 
al., 2007; Thomas and Fenech, 2008; Iourov et al., 2009; Arendt et al., 2010; Arendt, 
2012; Arendt et al., 2015). In addition, AD-causing mutations in the amyloid precursor 
protein (APP) and presenilin (PS) genes as well as exposure to amyloid-beta (A lead 
to mitotic spindle abnormalities and chromosome mis-segregation that depend on 
MAPT/Tau (Boeras et al., 2008; Granic et al., 2010). Furthermore, we discovered that a 
likely mechanism by which A causes spindle abnormalities and aneuploidy is through 
its competitive inhibition of the microtubule-dependent motor Kinesin-5/Eg5, which can 
be modulated by addition of MAPT/Tau (Borysov et al., 2011). These findings 
suggested that an FTLD-associated alteration in MAPT function may include 
chromosome mis-segregation as a contributing or even a necessary step in the 
neurodegenerative pathway. Indeed, lymphocytes from FTLD patients or from 
transgenic mice expressing human MAPT harboring FTLD-causing mutations exhibit 
chromosome instability, including aneuploidy (usually chromosome loss) (Rossi et al., 
2008; Rossi et al., 2013; Rossi et al., 2014). However, whether and how FTLD-causing 
mutations in MAPT affect mitosis, whether they affect chromosome segregation in the 
brain, and whether such cell cycle defects contribute to neurodegeneration in FTLD are 
unknown. 
 
Herein, we examined the effects of FTLD-causing MAPT mutations and loss of MAPT 
function in brain cell populations and/or in transfected cells and determined that defects 
in MAPT lead to aberrant mitotic spindle function, abnormal chromosome segregation, 
and apoptosis. Together, the data indicate that, as in AD, aneuploid neurons arise in the 
FTLD-MAPT brain, are prone to apoptosis, and can thus contribute to the development 
of neurodegeneration and dementia. 
 
 
 
Results 
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Aneuploidy Induced by Expression of Human MAPT Harboring FTLD-Causing 
Mutations in Mice 
Although overexpression of the human MAPT gene harboring familial FTLD-causing 
mutations (P301L or P301S) in mice has been shown to result in increased aneuploidy 
in splenic lymphocytes (Rossi et al., 2014), a key unanswered question with high 
disease relevance is whether FTLD-causing MAPT mutations also lead to aneuploidy in 
brain cells. We generated brain cell suspensions from young and older transgenic mice 
expressing human MAPT P301S or P301L and from age-matched control mice, and 
determined aneuploidy levels by fluorescence in situ hybridization (FISH) using a 
bacterial artificial chromosome (BAC) probe for mouse chromosome 16 (Kulnane et al., 
2002), which is partially syntenic with human chromosome 21. The data showed that 
expression of human mutant MAPT P301L induces a small but significant increase in 
chromosome 16 trisomy and total aneuploidy in the brain as early as eight weeks of age 
(Figure 1) with nearly undetectable levels of TUNEL-positive (apoptotic) cells (data not 
shown). A similar small but significant increase in aneuploidy was also detected in both 
brain cells (Figure 2A) and splenocytes (Figure 2B) from eight-month-old transgenic 
mice expressing mutant human MAPT P301S relative to non-transgenic control mice. 
 
Total or Partial Loss of Tau Function Induces Aneuploidy in Mouse Brain Neurons  
Our finding that expression in mice of human MAPT harboring FTLD-causing mutations 
resulted in increased levels of chromosome 16 aneuploidy in brain cells provided the 
first evidence that this mutation is not only associated with aneuploidy in peripheral cells 
(Rossi et al., 2008; Rossi et al., 2013; Rossi et al., 2014), but also with aneuploidy in the 
brain. Previously, we showed that splenocytes from tau (mapt) heterozygous (tau+/-) or 
homozygous (tau-/-) knockout mice exhibited 2.5% or 4.9% trisomy 16, respectively, 
compared to 1.1% stochastic trisomy in splenocytes from age-matched tau+/+ control 
mice (Granic et al., 2010). To further investigate the role of wild-type mouse Tau in 
chromosome segregation in the brain during neurogenesis and during post-natal 
neuronal development, we prepared single cell suspensions from brains of tau+/+, 
tau+/-, and tau-/- mice (aged 6–7 months) and analyzed both neurons and non-neuronal 
cells for chromosome 16 aneuploidy using chromosome-specific FISH and NeuN 
immunocytochemistry. Knocking out one, or, even more effectively, both copies of Tau 
led to a significant increase in aneuploid neurons (Figure 3A, B). This result shows that 
a total or even partial loss of Tau function, suggesting possible haploinsufficiency, in 
mice leads to a cell cycle defect in neuronal precursor cells that results in chromosome 
mis-segregation and mosaic aneuploidy.  
 
Elevated Levels of Mosaic Aneuploidy in Brain Neurons and Glia from FTLD 
Patients with MAPT Mutations 
Although we observed aneuploidy in mouse brain cells that was induced by expression 
of the P301L or P301S FTLD-causing form of human MAPT and in mouse brain 
neurons with complete or partial loss of Tau (Mapt) function, whether FLTD-associated 
mutations in MAPT lead to aneuploidy and subsequent apoptosis in the human brain, 
where they could affect neurodegeneration, is unknown. To address this question, we 
prepared single brain cell suspensions using frozen samples of cortex from familial 
FTLD patients with one of three different MAPT mutations, specifically MAPT P301L, 
MAPT N279K, or MAPT E372G (Table 1), or from normal controls and determined 
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aneuploidy levels using a dual-color DNA probe set to visualize chromosomes 12 and 
21 via FISH. We found that cortical brain cells from FTLD patients with MAPT mutations 
exhibit significantly higher levels of trisomy 12 and trisomy 21 relative to cortical brain 
cells from normal controls (Figure 4A). Furthermore, we observed significantly higher 
levels of mosaic aneuploidy (i.e., either monosomy or trisomy) for chromosomes 12 and 
21 in both neuronal [NeuN(+)] and non-neuronal [NeuN(-)] cells from the cortex relative 
to normal controls (Figure 4B). These results show that familial FTLD caused by MAPT 
mutations is characterized by mosaic aneuploidy, including trisomy 21, in both neurons 
and glia in the brain. 
  
Increased Apoptosis in Brain Neurons and Glia from FTLD Patients with MAPT 
Mutations Correlates with Induced Aneuploidy 
To ask directly whether aneuploidy and neurodegeneration are linked in FTLD, we 
measured apoptosis in cortical brain cells from the patients with MAPT mutations. 
Simultaneous terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) to 
detect apoptotic cells, NeuN staining to identify neurons, and chromosome 12 and 21 
FISH staining of brain samples from normal control subjects and familial FTLD patients 
with a MAPT mutation, including MAPT P301L, MAPT N279K, or MAPT E372G (Table 
1), showed that apoptosis was significantly increased in cortical brain cells from FTLD-
MAPT patients relative to normal controls (Figure 5A, E). Furthermore, the proportion of 
TUNEL(+)/apoptotic cells that were aneuploid (i.e., either monosomic or trisomic) for 
chromosome 12 or 21 reached around 80% in normal control brain cells and in brain 
cells from FTLD-MAPT patients (Figure 5B), despite the significant difference in the 
percentages of both aneuploid and apoptotic cells between control and FTLD brains, 
and this was true for both NeuN(+) neurons (Figure 5C) and NeuN(-) non-neuronal cells 
(Figure 5D). The large percentage of apoptotic cells that were aneuploid (i.e., 80%) 
contrasts with the much smaller percentage of aneuploid brain cells that were apoptotic 
(i.e., 20%) in both FTLD-MAPT patients and in normal control subjects (Figure 5F). 
Thus, while the normal control subjects had significantly lower overall levels of both 
apoptosis and aneuploidy (Figure 5A), our finding that the majority of apoptotic cells 
were aneuploid suggests that aneuploidy is a cause, rather than a consequence, of 
apoptosis. If aneuploidy was a consequence, rather than a cause, of apoptosis, we 
would have expected to find that the majority of aneuploid brain cells were 
apoptotic/TUNEL(+). Thus, our findings provide evidence that familial FTLD associated 
with MAPT mutations causes neurons and glia to become aneuploid, and that the 
aneuploid neurons and glia are then prone to undergoing apoptosis. These results 
mirror previous findings in AD showing that aneuploid neurons are particularly 
susceptible to degeneration (Arendt et al., 2010), but that some aneuploid neurons 
retain sufficient function to be incorporated into brain circuits (McConnell et al., 2013). In 
our experiments, chromosome segregation clearly affects both neuronal and non-
neuronal cells in familial FTLD patients with MAPT mutations. 
 
Expression of Human MAPT Genes Harboring FTLD-Causing Mutations Induces 
Aneuploidy and Subsequent Apoptosis in Karyotypically Normal Human Cells 
To rule out the possibility that pathological processes that arise in human FTLD-MAPT 
and in mutant MAPT mouse models are indirectly responsible for generating aneuploid 
neurons and glia, we transiently expressed human MAPT genes harboring one of two 
different FTLD-causing mutations in the karyotypically normal, non-neuronal hTERT-
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HME1 human cell line and assessed the levels of induced aneuploidy and apoptosis. As 
shown in Figure 6A and Supplemental Figure 1A-C and illustrated in Figure 6B and 
Supplemental Figure 1B, expression of FTLD-causing mutant forms of MAPT (P301L or 
V337M) induced a significant increase in aneuploidy within 48 h post-transfection, 
compared to control cells transfected with the vector alone. Levels of aneuploidy in cells 
transfected with wild-type MAPT were intermediate between those of cells transfected 
with the vector alone and cells transfected with the FTLD-causing MAPT mutants. At 
this 48 h time point, levels of apoptosis were essentially undetectable (data not shown).  
 
TUNEL staining at a later time point of 72 h post-transfection revealed significantly 
higher levels of apoptosis in cells expressing either MAPT P301L or MAPT V337M, 
relative to control cells transfected with the vector alone (Figure 6C). Quantitative 
analysis of cells co-stained for TUNEL and FISH for chromosomes 12 and 21 showed 
that the majority of TUNEL(+) cells at 72 h were aneuploid, regardless of whether they 
were negative controls or were expressing wild-type or mutant MAPT (Figure 6D,E). 
Analysis of the frequency of apoptosis among aneuploid cells and of aneuploidy among 
apoptotic cells at 72 h indicated that approximately 80% of apoptotic cells were 
aneuploid, but less than 20% of aneuploid cells were apoptotic (Figure 6F). This 
relationship between aneuploidy and apoptosis was true both in negative control cells, 
which had low levels of aneuploidy and apoptosis, and in cells expressing wild-type or 
mutant MAPT, which had significantly higher levels of aneuploidy and apoptosis. 
Notably, although the cells expressing the FLTD-causing mutant MAPT genes showed 
increased levels of aneuploidy at 48 h post-transfection, they did not exhibit increased 
levels of apoptosis until 72 h post-transfection. This finding suggests that aneuploidy 
precedes and most likely plays a causative role in the neuronal cell death that 
accompanies FTLD-MAPT.  
 
Apoptosis Induced by Expression of MAPT Harboring FTLD-Causing Mutations is 
Not Caused by Oxidative Stress  
Our data thus far show that FTLD-causing forms of human MAPT induce aneuploidy 
and apoptosis in human brain cells and when expressed in a karyotypically normal 
human cell line. The temporal order of aneuploidy followed by apoptosis in our cell 
culture experiments suggests a cause-effect relationship. However, it is theoretically 
possible that FTLD-associated MAPT mutations cause both aneuploidy and apoptosis 
through some common intermediate step. Indeed, oxidative stress has been described 
in transgenic mice expressing MAPT harboring the P301S FTLD mutation (Lopez-
Gonzalez et al., 2015). To test the possibility that FTLD-causing forms of MAPT induce 
oxidative stress, which in turn leads to both aneuploidy and apoptosis, we measured 
oxidative stress levels, including reactive oxygen species (ROS) and superoxide, in 
cells expressing the FTLD mutant forms of MAPT. In these experiments, we found no 
evidence of increased stress relative to controls (Supplemental Figure 2). These 
findings show that the effects of FTLD mutant MAPT on aneuploidy and apoptosis are 
not likely to be caused by oxidative stress. 
 
Expression of MAPT Harboring FTLD-Causing Mutations Induces Mitotic Spindle 
Defects in Karyotypically Normal Human Cells 
To investigate the mechanism by which MAPT dysfunction leads to chromosome mis-
segregation, aneuploidy, and subsequent apoptosis, we analyzed mitotic spindle 
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structures in hTERT-HME1 cells transfected with a vector for expressing wild-type 
MAPT, MAPT P301L, or MAPT V337M, or with the vector alone as a negative control 
(Figure 7). The cells transfected with either of the MAPT mutants exhibited increased 
levels of various types of mitotic spindle abnormalities, including lagging chromosomes, 
multiple centrosomes, and microtubule aggregates at 48 h post-transfection (Figure 7, 
D–J), when aneuploidy is observed but before apoptosis is observed. These data 
provide strong support for the conclusion that microtubule instability and consequent 
mitotic spindle dysfunction are a mechanism by which mutant MAPT induces 
chromosome mis-segregation, aneuploidy, and, ultimately, apoptosis. 
 
Mutant MAPT-induced Aneuploidy and Apoptosis Both Depend on Cell Division 
The data presented above are most consistent with the defects in mitosis and 
consequent chromosome mis-segregation and aneuploidy preceding and thus likely 
leading to apoptosis (Figure 8). As a more direct test of whether the aneuploidy caused 
by mutant MAPT expression induces apoptosis or whether the apoptosis caused by 
mutant MAPT expression occurs independently of the aneuploidy, hTERT-HME1 cells 
transfected with the pcDNA vector for expressing MAPT P301L or MAPT V337M, or 
with the pcDNA vector alone as a negative control were treated for 48 h with Nutlin-3 at 
24 h post-transfection to halt cell division and inhibit the generation of aneuploid cells. 
As expected, cells expressing mutant MAPT (P301L or V337M) exhibited significantly 
higher levels of aneuploidy (Supplemental Figure 3A) and apoptosis (Supplemental 
Figure 3B) relative to mock transfected cells, cells transfected with the pcDNA vector, or 
cells expressing wild-type MAPT; however, Nutlin-3 treatment of cells expressing 
mutant MAPT (P301L or V337M) prevented them from becoming aneuploid, as 
measured using a FISH probe for chromosome 21 (Supplemental Figure 3C), and it 
also prevented them from undergoing apoptosis, as measured by TUNEL staining 
(Supplemental Figure 3D). If the expression of mutant MAPT induces apoptosis 
independently of the aneuploidy, then we would have expected to observe increased 
apoptosis but not increased aneuploidy in the cells expressing mutant MAPT, since the 
Nutlin-3 treatment would prevent them from dividing and becoming aneuploid. However, 
the data clearly show that both mutant MAPT-induced aneuploidy and apoptosis were 
suppressed by Nutlin-3 treatment, indicating that the apoptosis is dependent on the 
aneuploidy caused by abnormal cell division (Supplemental Figure 3). 
 
Discussion 
Aneuploidy and Apoptosis in Various Neurodegenerative Diseases 
Previous studies have shown that aneuploidy occurs in neurons, glia, and other cells in 
sporadic and all familial forms of AD (Potter, 1991; Potter H, 1995; Migliore et al., 1997; 
Geller and Potter, 1999; Kingsbury et al., 2006; Mosch et al., 2007; Thomas and 
Fenech, 2008; Iourov et al., 2009), and that the specific degeneration of aneuploid 
neurons that occurs between mid-stage and advanced AD accounts for 90% of total 
neuronal cell loss observed at autopsy (Arendt et al., 2010; Arendt, 2012). Although 
chromosome instability was described previously in peripheral cells from FTLD patients 
with MAPT mutations (Rossi et al., 2008; Rossi et al., 2013), aneuploidy levels in the 
brain were not determined. 
 
Here, we show that the brains of familial FTLD patients with MAPT mutations exhibit 
significantly increased levels of mosaic aneuploidy for chromosomes 12 and 21, 
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together with a significant increase in apoptosis in both neuronal and non-neuronal 
cells. Furthermore, approximately 80% of the neuronal apoptosis occurs in the 
aneuploid neurons, which parallels the finding described above that 90% of neuronal 
cell death in advanced AD can be attributed to the specific loss of aneuploid neurons 
(Arendt et al., 2010).  
 
Our finding that apoptosis occurs preferentially in aneuploid cells from familial FTLD 
patients with MAPT mutations, including neurons, combined with our observation that a 
karyotypically normal human cell line expressing MAPT with an FTLD-causing mutation 
first exhibits aneuploidy without apoptosis at 48 h and then undergoes apoptosis at 72 h 
suggest that apoptosis arises from aneuploidy and not vice versa. This conclusion was 
tested directly by experiments with Nutlin-3 showing that the aneuploidy and the 
apoptosis induced by mutant MAPT expression in cultured cells are not independent of 
each other, because both require cell division. Our additional finding of mosaic 
aneuploidy in non-neuronal brain cells from FTLD patients with MAPT mutations 
reinforces the previous finding of chromosome instability in peripheral cells of FTLD 
patients with MAPT mutations (Rossi et al., 2008; Rossi et al., 2013) and indicates that 
chromosome mis-segregation is likely a general feature of all cells in patients with 
FTLD-MAPT. The fact that mitotic spindle abnormalities and aneuploidy arise within two 
mitotic cell cycles (at 48 h post-transfection) in karyotypically normal human cells 
expressing FTLD-causing mutant forms of MAPT and later lead to apoptosis provides a 
mechanistic link between microtubule dysfunction and neurodegeneration in FTLD-
MAPT. Over time, an individual with FTLD-MAPT who has carried one of these MAPT 
mutations in all of their cells for their entire life would be expected to also show 
significant levels of mosaic aneuploidy in cells throughout their body, and their 
aneuploid neurons would be at significant risk for apoptosis.  
 
The general cell cycle dysfunction shown in our FTLD-MAPT experiments and the 
similar findings in AD indicate that multiple chromosomes undergo mis-segregation in 
these and potentially other neurodegenerative diseases (Potter H, 1995; Migliore et al., 
1997; Geller and Potter, 1999; Kingsbury et al., 2006; Mosch et al., 2007; Boeras et al., 
2008; Thomas and Fenech, 2008; Iourov et al., 2009; Arendt et al., 2010; Granic et al., 
2010; Borysov et al., 2011; Arendt, 2012; Yurov et al., 2014; Arendt et al., 2015). For 
example, we have found that Niemann-Pick Type C1, another tauopathy, caused by 
defects in cholesterol metabolism, is characterized by aneuploid neurons and other cells 
(Granic and Potter, 2013). In addition, a recent study of Lewy body dementia showed an 
increase in neuronal DNA content (hyperdiploidy) that correlated with neuronal loss in 
all brain regions examined (Yang et al., 2015). These results together with our studies 
of AD and FTLD-MAPT support the general conclusion that aneuploid neurons arise by 
different mechanisms in multiple forms of neurodegenerative disease and that the 
increasing susceptibility of aneuploid neurons to apoptosis may underlie much of the 
neuronal loss and cognitive decline that characterize these disorders.  
 
Potential Means by Which Aneuploid Neurons Arise in MAPT-FTLD 
The generation and accumulation of aneuploidy in dividing cell populations might, in 
principle, arise by both genetic and environmental stressors at any time in life 
[discussed in (Potter, 1991; Oromendia and Amon, 2014)]. However, it has long been 
believed that neurons are post-mitotic cells and furthermore that vertebrates are born 
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with a finite number of neurons with little or no neurogenesis occurring in the adult brain 
(Bhardwaj et al., 2006). These long-held beliefs raise the question of when and how 
aneuploid neurons arise during age-associated neurodegenerative disease.  
 
Aneuploidy Generation During Embryogenesis. One explanation for neuronal 
aneuploidy in neurodegenerative diseases is that it arises in neuronal precursor cells 
during embryogenesis and then later leads to neurodegeneration. Certainly, our data 
show that having an FTLD-causing mutation in MAPT is sufficient to induce abnormal 
mitotic spindles and subsequent aneuploidy. However, the mechanism by which age 
may contribute to the process remains unclear. It is possible that aging may promote 
the development of additional processes that promote the degeneration of aneuploid 
neurons in these disorders (Potter, 1991; Potter et al., 2016).  
 
Aneuploidy Generated During Adult Neurogenesis and Aging. Although 
neurogenesis appears to be rare in normal adult brain, three processes may generate 
the neuronal aneuploidy observed at autopsy in patients with neurodegenerative 
diseases and may arise in the adult and be promoted by aging. First, data from many 
studies over the past couple of decades have provided evidence that neurogenesis can 
be induced in many brain regions in adult mice and rats in response to brain damage 
(Zhao et al., 2008; Spalding et al., 2013; Zheng et al., 2013; Ibrahim et al., 2016) and 
attempted self-repair by the brain, or as part of an ongoing process in the sub-
ventricular/granular zone of the brain (Eriksson et al., 1998; Hallbergson et al., 2003; 
Sakamoto et al., 2014). Therefore, neuronal damage and the mitotic defect in FTLD-
MAPT could produce aneuploid replacement neurons, which would not be fully 
functional and would be particularly prone to apoptosis and degeneration, as our 
experiments have shown. Aneuploidy has been shown to promote degeneration in 
many other experimental systems, possibly by inducing proteotoxic stress (Rajendran et 
al., 2008; Kai et al., 2009; Arendt et al., 2010; Oromendia and Amon, 2014).  
 
The second potential mechanism for aneuploidy generation during aging and 
neurodegeneration is cell cycle reentry. Neurons in the AD brain express phospho-
proteins usually detected only during mitosis (McShea et al., 1997; Vincent et al., 1997; 
Arendt, 2012), and in AD mice, the loss of pre-existing neurons induces neuronal 
reentry into the cell cycle (Lopes et al., 2009; Seward et al., 2013). Indeed, Aβ induces 
the expression of mitotic proteins and cell cycle reentry in mature neurons in culture
(Majd et al., 2008; Seward et al., 2013). A similar process may be occurring in familial 
FTLD associated with MAPT mutations.  
 
Finally, the recent discovery that striatal astrocytes can transdifferentiate into new 
neurons capable of forming functional neuronal circuits with pre-existing neurons 
following ischemic brain injury (Magnusson et al., 2014; Duan et al., 2015) suggests that 
the aneuploid glia we observed in FTLD brains may have the potential to 
transdifferentiate into the aneuploid neurons that we also observed. 
 
It seems very likely that the aging process may exacerbate any or all of these processes 
that have the potential to generate aneuploid neurons and other cells. Indeed, 
aneuploidy has been proposed and found to increase with age (Arendt et al., 2009; 
Yurov et al., 2009, 2010; Fischer et al., 2012).  
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Evidence that MAPT Plays a Role in Chromosome Segregation in both FTLD and 
AD 
Our studies showing that MAPT plays a role in chromosome segregation in some forms 
of FTLD is consistent with previous findings in AD, which showed that mutant forms of 
APP or PSEN1 or Aβ itself also induce chromosome mis-segregation in a MAPT-
dependent manner (Boeras et al., 2008; Granic et al., 2010; Borysov et al., 2011). 
Additionally, the fact that MAPT and APP phosphorylation and processing are cell cycle-
dependent modifications that increase during mitosis, and that MAPT, APP, and 
presenilin are localized to mitotic structures, such as centrosomes (Li et al., 1997; 
Sjoberg et al., 2006; Rossi et al., 2008; Judge et al., 2011), further implicates both 
MAPT and Aβ function in the process of chromosome segregation. 
 
Other Studies Linking Aneuploidy, Neurodegeneration and MAPT 
Evidence linking neuronal aneuploidy, neurodegeneration, and MAPT was reported 
recently by two other groups in Drosophila. Specifically, a study by Bougé and 
Parmentier showed that excess Tau causes mitotic spindle defects, aneuploidy, and 
apoptosis through inhibition of the microtubule-dependent motor protein Kinesin-5/Eg5 
(Bouge and Parmentier, 2016). Similar results have been observed by Malmanche et al. 
(2017), who examined photoreceptors and brain neurons in Drosophila and found that 
adult-onset neurodegeneration mediated by MAPT overexpression included the 
generation of aneuploid cells (Malmanche et al., 2017). The former result is of particular 
interest in light of our prior finding that A induces chromosome mis-segregation and 
aneuploidy though competitive inhibition of Kinesin-5/Eg5 (Borysov et al., 2011). Thus, 
causal mutations leading to AD and FTLD-MAPT appear to lead to chromosome mis-
segregation, aneuploidy, and apoptosis through inhibition of the same target enzyme: 
Kinesin-5/Eg5. 
 
Possible Explanations for How a General Cell Cycle Defect Can Lead to Regional 
Neurodegeneration 
Both AD and FTLD and indeed all neurodegenerative disease show pathology and cell 
loss in specific regions of the brain, while sparing other regions, and this regional 
specificity correlates roughly with the clinical symptoms (e.g., tau pathology in AD). 
Because APP and MAPT are expressed widely, other factors must control essential 
steps in the pathogenic pathway that results in regional specificity. In AD, the specificity 
arises from differences in the expression of modulator proteins, such as the amyloid 
catalysts alpha-1-antichymotrypsin (ACT) and ApoE, which are essential for the 
conversion of A to oligomers and filaments. Indeed, only A oligomers cause 
chromosome mis-segregation and aneuploidy (Granic et al., 2010; Borysov et al., 
2011). Both ACT and ApoE are inflammation-associated proteins in the brain that are 
not expressed highly in the cerebellum in AD, for example, where amyloid pathology 
also does not arise. Prion disease research has also found that species and regional 
specificity must involve a specific component, termed ‘protein X’, that is needed for 
pathology (Yehiely et al., 1997). Protein X has yet to be definitively identified, but one 
study showed that it is not ApoE (Tatzelt et al., 1996). 
The finding that APP and Presenilin mutations and their product, oligomeric A peptide, 
cause chromosome mis-segregation in cells, transgenic mice, and humans through 
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disruption of the mitotic spindle, and that the consequent aneuploidy may underlie much 
of the neurodegeneration, as discussed above, also begs the same question of how an 
effect on a common physiological process such as mitosis can lead to region specific 
neurodegeneration. As anticipated above, the explanation in AD may lie in the regional 
expression of ApoE. 
Similarly, we suggest that one potential explanation for the regional specificity of FTLD 
is that another protein that is expressed in the cortex interacts with mutant MAPT to 
promote its pathological effect on microtubules. It is also possible that such a protein or 
even the direct effect of mutant MAPT only occurs in dividing cells, as our experiment 
with Nutlin-3 indicates. In that case, only neurons undergoing cell cycle re-entry or being 
replaced by neurogenesis would be sensitive to mutant MAPT. Alternatively, other 
microtubule-binding proteins that can substitute for damaged tau may be normally 
preferentially expressed in certain brain regions (i.e. those not affected in FTLD), 
thereby underlying region-specific protection. 
 
Targeting Microtubule and Mitotic Spindle Dysfunction to Prevent 
Neurodegeneration  
Taken together with the results of our previous work and recent reports, the data 
presented herein provide a novel mechanism for neurodegeneration and neuronal 
dysfunction in FTLD based on microtubule and mitotic spindle dysfunction (Figure 8). 
Further, the findings may lead to new general treatments or preventative strategies for a 
wide range of neurodegenerative disorders, including FTLD, AD, Niemann Pick Type 
C1, ALS, Lewy body dementia, and DS. For example, microtubule stabilization, either 
by drug therapy, by inhibition of MAPT phosphorylation, or by rescue of inhibited 
Kinesin-5/Eg5 activity may improve chromosome segregation and lead to reduced 
levels of aneuploidy and subsequent neurodegeneration. 
 
Materials and Methods 
Cell Line 
The hTERT-HME1 (Clontech) is a telomerase-immortalized primary human mammary 
epithelial cell line that divides indefinitely and retains normal function, phenotype, and 
karyotype (Jiang et al., 1999). The cell line was cultured in supplemented Mammary 
Epithelium Basal Medium (MEBM, Lonza), as described previously (Boeras et al., 2008; 
Granic et al., 2010). Early cell passages were used for the experiments. 
 
Primary Mouse Cells 
Mouse spleens and brains were harvested and processed for culture or immediately 
fixed as single cell suspensions for FISH and FISH/immunocytochemistry, as described 
previously (Boeras et al., 2008; Granic et al., 2010; Granic and Potter, 2013; Caneus et 
al., 2017). 
 
Human Brain Cells  
Approximately 1–2 g of frozen human brain cortices from patients diagnosed with 
familial FTLD associated with MAPT mutations (aged 56 ± 5 years) and controls (aged 
65 ± 9 years; p = 0.054) were obtained from the Mayo Clinic Brain Bank and the Banner 
Sun Health Research Institute and Brain and Body Donation Program, respectively. The 
tissues were dissociated into single nuclei suspensions, fixed and processed for FISH in 
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combination with NeuN and/or TUNEL immunocytochemistry, as described previously 
(Granic et al., 2010; Granic and Potter, 2013). 
 
Mice 
Tau-/- knockout mice [obtained from the Jackson Laboratory, B6.129X1-MAPTtm1Hnd/J, 
(Dawson et al., 2001)], and their heterozygous (tau+/-) and wild-type (tau+/+) littermates 
were 6–7 months old (background strain: C57BL/6). Transgenic mice expressing a 
human FTLD-causing mutation in the MAPT gene (P301S) from a prion promoter and 
their non-transgenic control (NON) were ~8 months old and were obtained from the 
Jackson Laboratory [B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J]. In addition, brain tissue 
samples from an FTLD mouse model expressing the human mutant MAPT (P301L) 
transgene under the control of the prion promoter and control non-transgenic mice (~ 8 
weeks old) were purchased from the Jackson Laboratory [FVB-Tg(tetO-
MAPT*P301L)#Kha/JlwsJ and FVB/NJ, respectively]. 
 
Plasmids 
Plasmids constructed by inserting the wild-type human MAPT cDNA or the human 
MAPT cDNA harboring an FTLD-causing mutation (P301L or V337M) into the 
pcDNA3.1 expression vector were gifts from Dr. Chad Dickey (University of South 
Florida, Tampa). The NucleoBond Plasmid Purification Kit (BD Bioscience) was used for 
nucleic acid extraction from NovaBlue SinglesTM competent cells (Novagen®). 
 
Antibodies, Kits, and DNA Probes 
Mouse/rabbit anti-neuronal nuclei (NeuN) AlexaFluor® antibodies (Millipore, MAB377X; 
Abcam, ab190195) and DAPI II (Abbott, Vysis) or VectaShield with DAPI (Vector 
Laboratories) were used to label neurons and nuclei, respectively. A BAC probe to 
mouse chromosome 16 was either purchased (Mouse IDetect Chromosome 16 
D16Mit88 Point Probe, RP24-288N19, Empire Genomics) or prepared directly using a 
Nick Translation Kit (Roche) with Spectrum Green or Red dUTP (Vysis) using a 
chromosome 16 BAC plasmid (a gift from Dr. Bruce Lamb), as described previously 
(Boeras et al., 2008; Granic et al., 2010; Granic and Potter, 2013). A mixture of 
fluorescently labeled DNA probes for the detection of human chromosomes 12 and 21 
(LSI® TEL/AML1 ES Dual Color Translocation Probe) or individual probes for the 
detection of human chromosome 21 (Vysis TelVysion 21q SpectrumOrange Probe, 
Vysis LSI ERG (Tel) SpectrumGreen Probe, Vysis LSI ERG (Cen) SpectrumRed 
Probe,) were obtained from Abbott, Vysis. TUNEL assay was carried out using the 
Click-iT Plus TUNEL Assay for in situ apoptosis detection with Alexa Fluor dyes 
(molecular probes) on brain samples and cultured cells in with or without Nutlin-3 
(Selleckchem, Cat. No. S1061). A cellular ROS/Superoxide Detection Assay Kit 
(Abcam, ab139476) was used to measure oxidative stress levels in cultured cells. 
 
FISH Analysis 
Single nuclei suspensions were dropped on glass slides (FisherBrand) and air-
dried/aged at room temperature overnight. The slides/nuclei were then subjected to 
hybridization procedures according to the manufacturer (Abbott, Vysis) using 
established protocols with the mouse and human probes described above and 
previously, including hybridization in a HyBrite chamber (Vysis). In subsequent steps, 
the slides were either counterstained with Vectashield with DAPI immediately (cultured 
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cells) or processed for NeuN immunostaining followed by DAPI counterstain (brain 
samples) (Boeras et al., 2008; Granic et al., 2010; Granic and Potter, 2013; Caneus et 
al., 2017).  
 
TUNEL Staining Combined with FISH and Immunocytochemistry for Brain Cells 
Single nuclei suspensions prepared from either frozen human brain tissues or from 
hTERT cells transfected for 72 h with mutant MAPT genes were fixed, dropped, and air-
dried overnight on glass slides, and subjected to TUNEL staining, which involved 
incubation with a recombinant terminal deoxynucleotidyl transferase (TdT) and dUTPs 
with Alexa Fluor dyes for a combined 1 h, 40 min at 37˚C, according to the 
manufacturer’s recommended procedure (Click-iT Plus TUNEL Assay, Life 
Technologies). Following TUNEL staining, the cells were processed for FISH with DNA 
probes for chromosomes 12 and 21, and immunocytochemistry with anti-NeuN 
antibodies (Millipore and Abcam), as described previously. On average, more than 500 
cells/slide and three slides/sample were counted for the transfected hTERT cells, and 
~1,000 cells/slide and two slides were counted for each human subject. 
 
Transient Transfection 
The hTERT-HME1 cells (~1.8 x 105 cells/2 ml) were plated into a six-well plate and 
transfected with an empty pcDNA3.1 vector, with the pcDNA3.1 vector harboring a wild-
type or mutant (P301L or V337M) human MAPT cDNA, or with a mixture of reduced 
Opti-MEM and FuGENE® 6 transfection reagent (Promega), according to the 
manufacturer’s protocol, as described previously (Boeras et al., 2008; Granic et al., 
2010). Cells from three parallel transfections were treated with Nutlin-3 at 24 h post-
transfection and incubated for an additional 48 h. The samples were then harvested, 
fixed, and scored for aneuploidy using chromosome 21 FISH and apoptosis using 
TUNEL at 72 h post-transfection. 
 
Immunocytochemistry of hTERT-HME1 Cells for Microtubule Analyses 
Confluent hTERT cells were harvested, plated at a density of ~1.5 x 105 cells/2 ml and 
treated with the FuGENE® 6 reagent alone or transfected with a FuGene 6-DNA 
complex of either the plasmid vector (pcDNA3.1) or the pcDNA3.1 plasmid vector 
harboring wild-type MAPT, MAPT V337M, or MAPT P301L, and cultured on glass 
chamber slides. The cells were allowed to progress through the cell cycle and harvested 
at the metaphase/anaphase stages of mitosis, fixed in methanol for 5 min at -20˚C, 
subjected to indirect immunofluorescence staining with a mouse anti-alpha-tubulin 
antibody (Abcam; Cat. Ab28439) and Alexa Fluor-conjugated goat anti-mouse antibody, 
and mounted in Vectashield with DAPI. 
 
Image Acquisition and Analysis 
FISH hybridization signals were analyzed following Abbott/Vysis guidelines as 
described (Boeras et al., 2008; Granic et al., 2010). Between 800 and 1,000 interphases 
per sample per treatment were scored for aneuploidy, and at least 400 NeuN(+) and 
NeuN(-) mouse brain cells were analyzed for BAC DNA signals. In addition, the 
percentage of cells that were positive for TUNEL labeling were recorded and scored for 
apoptosis analysis. Mitotic spindles and DNA were visualized and scored for 
quantitative analysis using ZEN 2011 SP1 imaging software. Each of the in vitro 
experiments were done in triplicate. 
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Statistics 
Normality of data was determined by Shapiro-Wilk test. Independent T-tests were used 
to compare aneuploidy in FTLD and control brain and spleen cells in the experiments 
using transgenic mice expressing human MAPT P301S. One-Way ANOVA with Tukey 
HSD and Dunnett test was used to establish significance in all other studies, as 
indicated by (*) or presented in the figures. The effect size (ŋ2 for ANOVA, and Cohen’s 
d for T-test) was calculated for the main outcomes. The analyses were performed in 
Microsoft Excel 2013 and IBM SPSS Statistics version 22. 
15 
 
 
Acknowledgements 
The chromosome 16 BAC and MAPT expression vectors were kind gifts from Dr. Bruce 
Lamb and Dr. Chad Dickey, respectively. We also acknowledge with gratitude the 
contributions of neurologists, notably Drs. Neill Graff-Radford and Zbigniew Wszolek, in 
caring for the FTLD patients. Human brain tissue was obtained from the Mayo Clinic 
Brain Bank, Jacksonville, FL, and from the Banner Sun Health Research Institute Brain 
and Body Donation Program of Sun City, AZ, which is supported by the National 
Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and 
Tissue Resource for Parkinson’s Disease and Related Disorders), the National Institute 
on Aging (P30 AG19610, Arizona Alzheimer’s Disease Core Center), the Arizona 
Department of Health Services (contract 211002, Arizona Alzheimer’s Research 
Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901, 
and 1001 to the Arizona Parkinson's Disease Consortium), and the Michael J. Fox 
Foundation for Parkinson’s Research. We appreciate the opportunity to present early 
results of this study at the 2013, 2014, and 2015 Alzheimer’s Association International 
Conferences. We also thank Dr. Joaquin Espinosa for his helpful suggestion to use 
Nutlin-3 to inhibit cell division in our experiments. This study was funded by National 
Institute of Aging (NIA) grants (AG025711; AG037942). AG is funded by the AGE 
Research Group to Prof. Avan A. Sayer (Institute of Neuroscience, Newcastle Institute 
for Ageing, the National Institute for Health Research Newcastle Biomedical Research 
Centre, Newcastle University, UK). The authors also acknowledge the generous support 
of donors.  
  
16 
 
References Cited 
 
Arendt, T. (2012). Cell cycle activation and aneuploid neurons in Alzheimer's disease. 
Molecular neurobiology 46, 125-135. 
Arendt, T., Bruckner, M.K., and Losche, A. (2015). Regional mosaic genomic 
heterogeneity in the elderly and in Alzheimer's disease as a correlate of neuronal 
vulnerability. Acta neuropathologica 130, 501-510. 
Arendt, T., Bruckner, M.K., Mosch, B., and Losche, A. (2010). Selective cell death of 
hyperploid neurons in Alzheimer's disease. The American journal of pathology 177, 15-
20. 
Arendt, T., Mosch, B., and Morawski, M. (2009). Neuronal aneuploidy in health and 
disease: a cytomic approach to understand the molecular individuality of neurons. Int J 
Mol Sci 10, 1609-1627. 
Bhardwaj, R.D., Curtis, M.A., Spalding, K.L., Buchholz, B.A., Fink, D., Bjork-Eriksson, 
T., Nordborg, C., Gage, F.H., Druid, H., Eriksson, P.S., and Frisen, J. (2006). 
Neocortical neurogenesis in humans is restricted to development. Proceedings of the 
National Academy of Sciences of the United States of America 103, 12564-12568. 
Boeras, D.I., Granic, A., Padmanabhan, J., Crespo, N.C., Rojiani, A.M., and Potter, H. 
(2008). Alzheimer's presenilin 1 causes chromosome missegregation and aneuploidy. 
Neurobiology of aging 29, 319-328. 
Borysov, S.I., Granic, A., Padmanabhan, J., Walczak, C.E., and Potter, H. (2011). 
Alzheimer Abeta disrupts the mitotic spindle and directly inhibits mitotic microtubule 
motors. Cell cycle 10, 1397-1410. 
Bouge, A.L., and Parmentier, M.L. (2016). Tau excess impairs mitosis and kinesin-5 
function, leading to aneuploidy and cell death. Disease models & mechanisms 9, 307-
319. 
Caneus, J., Granic, A., Chial, H.J., and Potter, H. (2017). Using Fluorescence In Situ 
Hybridization (FISH) Analysis to Measure Chromosome Instability and Mosaic 
Aneuploidy in Neurodegenerative Diseases. In: Genomic Mosaicism in Neurons and 
Other Cell Types, vol. 131, eds. J.M. Frade and F.H. Gage: Humana Press, 329-359. 
Dawson, H.N., Ferreira, A., Eyster, M.V., Ghoshal, N., Binder, L.I., and Vitek, M.P. 
(2001). Inhibition of neuronal maturation in primary hippocampal neurons from tau 
deficient mice. Journal of cell science 114, 1179-1187. 
Duan, C.L., Liu, C.W., Shen, S.W., Yu, Z., Mo, J.L., Chen, X.H., and Sun, F.Y. (2015). 
Striatal astrocytes transdifferentiate into functional mature neurons following ischemic 
brain injury. Glia 63, 1660-1670. 
17 
 
Eriksson, P.S., Perfilieva, E., Bjork-Eriksson, T., Alborn, A.M., Nordborg, C., Peterson, 
D.A., and Gage, F.H. (1998). Neurogenesis in the adult human hippocampus. Nat Med 
4, 1313-1317. 
Fischer, H.G., Morawski, M., Bruckner, M.K., Mittag, A., Tarnok, A., and Arendt, T. 
(2012). Changes in neuronal DNA content variation in the human brain during aging. 
Aging cell 11, 628-633. 
Geller, L.N., and Potter, H. (1999). Chromosome missegregation and trisomy 21 
mosaicism in Alzheimer's disease. Neurobiology of disease 6, 167-179. 
Granic, A., Padmanabhan, J., Norden, M., and Potter, H. (2010). Alzheimer Abeta 
peptide induces chromosome mis-segregation and aneuploidy, including trisomy 21: 
requirement for tau and APP. Molecular biology of the cell 21, 511-520. 
Granic, A., and Potter, H. (2013). Mitotic spindle defects and chromosome mis-
segregation induced by LDL/cholesterol-implications for Niemann-Pick C1, Alzheimer's 
disease, and atherosclerosis. PloS one 8, e60718. 
Hallbergson, A.F., Gnatenco, C., and Peterson, D.A. (2003). Neurogenesis and brain 
injury: managing a renewable resource for repair. The Journal of clinical investigation 
112, 1128-1133. 
Ibrahim, S., Hu, W., Wang, X., Gao, X., He, C., and Chen, J. (2016). Traumatic Brain 
Injury Causes Aberrant Migration of Adult-Born Neurons in the Hippocampus. Sci Rep 
6, 21793. 
Iourov, I.Y., Vorsanova, S.G., Liehr, T., and Yurov, Y.B. (2009). Aneuploidy in the 
normal, Alzheimer's disease and ataxia-telangiectasia brain: differential expression and 
pathological meaning. Neurobiology of disease 34, 212-220. 
Jiang, X.R., Jimenez, G., Chang, E., Frolkis, M., Kusler, B., Sage, M., Beeche, M., 
Bodnar, A.G., Wahl, G.M., Tlsty, T.D., and Chiu, C.P. (1999). Telomerase expression in 
human somatic cells does not induce changes associated with a transformed 
phenotype. Nature genetics 21, 111-114. 
Judge, M., Hornbeck, L., Potter, H., and Padmanabhan, J. (2011). Mitosis-specific 
phosphorylation of amyloid precursor protein at threonine 668 leads to its altered 
processing and association with centrosomes. Molecular neurodegeneration 6, 80. 
Kai, Y., Wang, C.C., Kishigami, S., Kazuki, Y., Abe, S., Takiguchi, M., Shirayoshi, Y., 
Inoue, T., Ito, H., Wakayama, T., and Oshimura, M. (2009). Enhanced apoptosis during 
early neuronal differentiation in mouse ES cells with autosomal imbalance. Cell 
research 19, 247-258. 
Kingsbury, M.A., Yung, Y.C., Peterson, S.E., Westra, J.W., and Chun, J. (2006). 
Aneuploidy in the normal and diseased brain. Cellular and molecular life sciences : 
CMLS 63, 2626-2641. 
18 
 
Kulnane, L.S., Lehman, E.J., Hock, B.J., Tsuchiya, K.D., and Lamb, B.T. (2002). Rapid 
and efficient detection of transgene homozygosity by FISH of mouse fibroblasts. Mamm 
Genome 13, 223-226. 
Li, J., Xu, M., Zhou, H., Ma, J., and Potter, H. (1997). Alzheimer presenilins in the 
nuclear membrane, interphase kinetochores, and centrosomes suggest a role in 
chromosome segregation. Cell 90, 917-927. 
Lopes, J.P., Blurton-Jones, M., Yamasaki, T.R., Agostinho, P., and LaFerla, F.M. 
(2009). Activation of cell cycle proteins in transgenic mice in response to neuronal loss 
but not amyloid-beta and tau pathology. Journal of Alzheimer's disease : JAD 16, 541-
549. 
Lopez-Gonzalez, I., Aso, E., Carmona, M., Armand-Ugon, M., Blanco, R., Naudi, A., 
Cabre, R., Portero-Otin, M., Pamplona, R., and Ferrer, I. (2015). Neuroinflammatory 
Gene Regulation, Mitochondrial Function, Oxidative Stress, and Brain Lipid 
Modifications With Disease Progression in Tau P301S Transgenic Mice as a Model of 
Frontotemporal Lobar Degeneration-Tau. Journal of neuropathology and experimental 
neurology 74, 975-999. 
Magnusson, J.P., Goritz, C., Tatarishvili, J., Dias, D.O., Smith, E.M., Lindvall, O., 
Kokaia, Z., and Frisen, J. (2014). A latent neurogenic program in astrocytes regulated 
by Notch signaling in the mouse. Science 346, 237-241. 
Majd, S., Zarifkar, A., Rastegar, K., and Takhshid, M.A. (2008). Different fibrillar Abeta 
1-42 concentrations induce adult hippocampal neurons to reenter various phases of the 
cell cycle. Brain research 1218, 224-229. 
Malmanche, N., Dourlen, P., Gistelinck, M., Demiautte, F., Link, N., Dupont, C., Vanden 
Broeck, L., Werkmeister, E., Amouyel, P., Bongiovanni, A., Bauderlique, H., Moechars, 
D., Royou, A., Bellen, H.J., Lafont, F., Callaerts, P., Lambert, J.C., and Dermaut, B. 
(2017). Developmental Expression of 4-Repeat-Tau Induces Neuronal Aneuploidy in 
Drosophila Tauopathy Models. Sci Rep 7, 40764. 
McConnell, M.J., Lindberg, M.R., Brennand, K.J., Piper, J.C., Voet, T., Cowing-Zitron, 
C., Shumilina, S., Lasken, R.S., Vermeesch, J.R., Hall, I.M., and Gage, F.H. (2013). 
Mosaic copy number variation in human neurons. Science 342, 632-637. 
McShea, A., Harris, P.L., Webster, K.R., Wahl, A.F., and Smith, M.A. (1997). Abnormal 
expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. The 
American journal of pathology 150, 1933-1939. 
Migliore, L., Testa, A., Scarpato, R., Pavese, N., Petrozzi, L., and Bonuccelli, U. (1997). 
Spontaneous and induced aneuploidy in peripheral blood lymphocytes of patients with 
Alzheimer's disease. Human genetics 101, 299-305. 
Mosch, B., Morawski, M., Mittag, A., Lenz, D., Tarnok, A., and Arendt, T. (2007). 
Aneuploidy and DNA replication in the normal human brain and Alzheimer's disease. 
19 
 
The Journal of neuroscience : the official journal of the Society for Neuroscience 27, 
6859-6867. 
Oromendia, A.B., and Amon, A. (2014). Aneuploidy: implications for protein 
homeostasis and disease. Disease models & mechanisms 7, 15-20. 
Potter, H. (1991). Review and hypothesis: Alzheimer disease and Down syndrome--
chromosome 21 nondisjunction may underlie both disorders. American journal of human 
genetics 48, 1192-1200. 
Potter, H., Granic, A., and Caneus, J. (2016). Role of Trisomy 21 Mosaicism in Sporadic 
and Familial Alzheimer's Disease. Current Alzheimer research 13, 7-17. 
Potter H, M.J., Das S, Geller LN, Benjamin M, Kayyali US and Dressler D. (1995). 
Beyond β-protein: New steps in the pathogenic pathway to Alzheimer's disease. . In: 
Research Advances in Alzheimer’s Disease and Related Disorders, ed. J.A.M. K. Iqbal, 
B. Winblad, and H.M. Wisniewski John Wiley and Sons Ltd., 643-654. 
Rademakers, R., Neumann, M., and Mackenzie, I.R. (2012). Advances in understanding 
the molecular basis of frontotemporal dementia. Nature reviews. Neurology 8, 423-434. 
Rajendran, R.S., Wellbrock, U.M., and Zupanc, G.K. (2008). Apoptotic cell death, long-
term persistence, and neuronal differentiation of aneuploid cells generated in the adult 
brain of teleost fish. Developmental neurobiology 68, 1257-1268. 
Rossi, G., Conconi, D., Panzeri, E., Paoletta, L., Piccoli, E., Ferretti, M.G., Mangieri, M., 
Ruggerone, M., Dalpra, L., and Tagliavini, F. (2014). Mutations in MAPT give rise to 
aneuploidy in animal models of tauopathy. Neurogenetics 15, 31-40. 
Rossi, G., Conconi, D., Panzeri, E., Redaelli, S., Piccoli, E., Paoletta, L., Dalpra, L., and 
Tagliavini, F. (2013). Mutations in MAPT gene cause chromosome instability and 
introduce copy number variations widely in the genome. Journal of Alzheimer's disease 
: JAD 33, 969-982. 
Rossi, G., Dalpra, L., Crosti, F., Lissoni, S., Sciacca, F.L., Catania, M., Di Fede, G., 
Mangieri, M., Giaccone, G., Croci, D., and Tagliavini, F. (2008). A new function of 
microtubule-associated protein tau: involvement in chromosome stability. Cell cycle 7, 
1788-1794. 
Sakamoto, M., Ieki, N., Miyoshi, G., Mochimaru, D., Miyachi, H., Imura, T., Yamaguchi, 
M., Fishell, G., Mori, K., Kageyama, R., and Imayoshi, I. (2014). Continuous postnatal 
neurogenesis contributes to formation of the olfactory bulb neural circuits and flexible 
olfactory associative learning. The Journal of neuroscience : the official journal of the 
Society for Neuroscience 34, 5788-5799. 
Seward, M.E., Swanson, E., Norambuena, A., Reimann, A., Cochran, J.N., Li, R., 
Roberson, E.D., and Bloom, G.S. (2013). Amyloid-beta signals through tau to drive 
ectopic neuronal cell cycle re-entry in Alzheimer's disease. Journal of cell science 126, 
1278-1286. 
20 
 
Sjoberg, M.K., Shestakova, E., Mansuroglu, Z., Maccioni, R.B., and Bonnefoy, E. 
(2006). Tau protein binds to pericentromeric DNA: a putative role for nuclear tau in 
nucleolar organization. Journal of cell science 119, 2025-2034. 
Spalding, K.L., Bergmann, O., Alkass, K., Bernard, S., Salehpour, M., Huttner, H.B., 
Bostrom, E., Westerlund, I., Vial, C., Buchholz, B.A., Possnert, G., Mash, D.C., Druid, 
H., and Frisen, J. (2013). Dynamics of hippocampal neurogenesis in adult humans. Cell 
153, 1219-1227. 
Tatzelt, J., Maeda, N., Pekny, M., Yang, S.L., Betsholtz, C., Eliasson, C., Cayetano, J., 
Camerino, A.P., DeArmond, S.J., and Prusiner, S.B. (1996). Scrapie in mice deficient in 
apolipoprotein E or glial fibrillary acidic protein. Neurology 47, 449-453. 
Thomas, P., and Fenech, M. (2008). Chromosome 17 and 21 aneuploidy in buccal cells 
is increased with ageing and in Alzheimer's disease. Mutagenesis 23, 57-65. 
Vincent, I., Jicha, G., Rosado, M., and Dickson, D.W. (1997). Aberrant expression of 
mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 17, 3588-
3598. 
Yang, Y., Shepherd, C., and Halliday, G. (2015). Aneuploidy in Lewy body diseases. 
Neurobiology of aging 36, 1253-1260. 
Yehiely, F., Bamborough, P., Da Costa, M., Perry, B.J., Thinakaran, G., Cohen, F.E., 
Carlson, G.A., and Prusiner, S.B. (1997). Identification of candidate proteins binding to 
prion protein. Neurobiology of disease 3, 339-355. 
Yurov, Y.B., Vorsanova, S.G., and Iourov, I.Y. (2009). GIN'n'CIN hypothesis of brain 
aging: deciphering the role of somatic genetic instabilities and neural aneuploidy during 
ontogeny. Mol Cytogenet 2, 23. 
Yurov, Y.B., Vorsanova, S.G., and Iourov, I.Y. (2010). Ontogenetic variation of the 
human genome. Current genomics 11, 420-425. 
Yurov, Y.B., Vorsanova, S.G., Liehr, T., Kolotii, A.D., and Iourov, I.Y. (2014). X 
chromosome aneuploidy in the Alzheimer's disease brain. Mol Cytogenet 7, 20. 
Zhao, C., Deng, W., and Gage, F.H. (2008). Mechanisms and functional implications of 
adult neurogenesis. Cell 132, 645-660. 
Zheng, W., ZhuGe, Q., Zhong, M., Chen, G., Shao, B., Wang, H., Mao, X., Xie, L., and 
Jin, K. (2013). Neurogenesis in adult human brain after traumatic brain injury. J 
Neurotrauma 30, 1872-1880.  
21 
 
 
Figure 1. Increased Percentage of Cells 
with Abnormal Chromosome Numbers in Brain Tissues from Young Transgenic 
Mice Expressing a Human Mutant FTLD-MAPT Gene. 
FISH analysis using a mouse chromosome 16 probe was carried out using single nuclei 
suspensions prepared with brain tissues from eight-week-old transgenic mice 
expressing a human mutant MAPT transgene (MAPT-P301L, n = 4). Brain tissues from 
the transgenic mice exhibited elevated levels of trisomy 16 (A) and total chromosome 
16 aneuploidy (including monosomy plus trisomy) (B) in comparison to control non-
transgenic mice (Control, n = 4). Both neurons [NeuN(+), green] and non-neuronal cells 
[NeuN(-)] showed abnormal chromosome copy numbers in the FTLD-MAPT mice (C). 
For statistical analyses, more than 300 cells per slide and three slides per brain sample 
were counted. Statistical analyses were conducted using a student t-test. Error bars 
indicate SEM, and * indicates P < 0.05. 
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Figure 2. Trisomy 16 Induced by the Expression of Human MAPT Harboring the 
P301S FTLD-Causing Mutation in Brain and Spleen Cells from Older Mice 
Brains and spleens were harvested from eight-month-old transgenic mice expressing 
the human MAPT gene harboring the FTLD-causing P301S mutation (MAPT-P301S) 
and from age-matched control mice (NON). Single brain cell suspensions and 
splenocyte cultures were prepared and analyzed for aneuploidy by FISH using a mouse 
chromosome 16 BAC probe. The data show that expression of MAPT-P301S induces 
chromosome mis-segregation in brain cells (A) and in splenocytes (B) (independent T-
test, one-tailed; effect size Cohen’s d of 1.54 and 1.69, respectively). 
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Figure 3. Complete or Partial Loss of Tau Function Induces Trisomy 16 in Mouse 
Neurons  
Single cell suspensions of brain cells from tau+/+, tau+/-, and tau-/- mice were analyzed 
by FISH using a mouse chromosome 16 BAC DNA probe and co-stained with the anti-
NeuN antibody to identify neurons. Quantitative analysis of BAC signals (Spectrum 
Orange d-UTPs) revealed a significant increase in trisomy 16 in neurons from tau +/- 
and tau-/- mice compared to tau+/+ mice (A). The graph shows mean difference 
between groups using ANOVA with Tukey HSD post hoc (effect size ŋ2 = 0.75 for 
neurons). Representative examples of tau+/- and tau-/- neurons [NeuN(+), green] and 
glia [NeuN(-)] are shown (B). 
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Figure 4. Increased Levels of Mosaic Aneuploidy in Brain Neurons and Glia from 
FTLD Patients with MAPT Mutations  
Quantitative FISH analysis of single cell suspensions prepared from frozen cortical brain 
samples of individuals genetically identified as having familial FTLD with a mutation in 
MAPT (MAPT-FTLD) (n = 4) compared with normal controls (n = 7) revealed 
significantly higher percentages of brain cells with trisomy 12 or 21 in FTLD-MAPT 
patients (A). Separated analysis of neurons [NeuN(+)]from other brain cells [NeuN(-)] 
showed increased total aneuploidy (i.e., monosomy or trisomy for chromosome 12 or 
21) in both cortical neurons and glia from familial FTLD patients relative to normal 
controls (B). The graphs show mean difference and significance (*) using One-Way 
ANOVA with Tukey post hoc test. Error bars indicate SEM. *, P < 0.05; **, P < 0.005; 
and ***, P < 0.0005. A minimum of ~1,000 nuclei/slide and three slides/sample were 
counted and recorded for statistical analyses. 
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Figure 5. Apoptosis in Aneuploid Brain Neurons and Glia from FTLD Patients with 
MAPT Mutations  
Co-staining for TUNEL, NeuN, and FISH for chromosomes 12 and 21 revealed higher 
levels of apoptosis, indicated by TUNEL(+) staining, in cortical brain cells from FTLD 
patients with MAPT mutations (MAPT-FTLD) relative to normal control subjects 
(Control) (A). Quantitative analysis showed that the majority of cells that were 
TUNEL(+)/apoptotic were aneuploid (i.e., monosomic or trisomic for chromosome 12 or 
21), regardless of whether they were from normal control subjects or from FTLD-MAPT 
patients (B). Further, a similarly large percentage of the TUNEL(+), NeuN(+) neuronal 
cells (C) and TUNEL(+), NeuN(-) glial cells (D) were aneuploid in both normal control 
subjects and FTLD-MAPT patients. (E) Images of an aneuploid FTLD-MAPT (P301L) 
cell with three copies of chromosome 21 and one copy of chromosome 12 (I) showing 
NeuN (II); and TUNEL staining (III); FISH for chromosomes 12 and 21 with DAPI (IV); 
TUNEL, NeuN, and FISH for chromosomes 12 and 21 (V); and a merged image of 
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TUNEL (red), NeuN (green), FISH for chromosomes 12 (green) and 21 (orange/red), 
and DAPI (blue) (VI). Notably, although the probe signals are very distinct and easily 
distinguishable when viewed through the eyepieces of the microscope, it is difficult to 
show this in the captured images, since the emission wavelengths for the FISH probes 
and the NeuN/TUNEL staining show some overlap. Analysis of the frequency of 
apoptosis among aneuploid brain cells and of aneuploidy among apoptotic brain cells 
indicates that around 80% of apoptotic cells were aneuploid in both control brains and 
FTLD-MAPT brains, whereas less than 20% of aneuploid cells were apoptotic in both 
control brains and FTLD-MAPT brains (F). More than 1,000 cells per slide and three 
slides per sample were scored for statistical analysis. Statistical significances were 
calculated using student t-test. Error bars indicated SEM. *, P < 0.05; **; P < 0.005; and 
***, P < 0.0005 
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Figure 6. Induction of Trisomy 12 and 21 Followed by Apoptosis in Karyotypically 
Normal Human Cells Expressing MAPT Harboring FTLD-Causing Mutations  
Quantitative FISH analysis of hTERT-HME1 cells transfected in the absence of vector 
(Reagent), with the pcDNA3.1 vector alone (pcDNA), or with the pcDNA3.1 vector 
harboring wild-type MAPT (WT-MAPT), MAPT with the P301L mutation (P301L), or 
MAPT with the V337M mutation (V337M) revealed an increase in trisomy 12 (green) 
and trisomy 21 (orange) in cells expressing MAPT with the FTLD-causing mutations 
(P301L or V337M) at 48 h compared to cells transfected with the vector alone (A). 
Levels of aneuploidy in cells transfected with wild-type MAPT were intermediate 
between cells transfected with the vector alone and cells transfected with the FTLD-
causing MAPT mutants. A representative cell with trisomy for chromosomes 12 (green) 
and 21 (red) showing three individual signals for each chromosome at 48 h is shown in 
(B). Co-staining for TUNEL (green) and FISH for chromosomes 12 and 21 at 72 h 
revealed a significant increase in apoptosis, indicated by TUNEL(+) staining, in cells 
expressing MAPT with the P301L or V337M mutation relative to negative control cells 
28 
 
(Reagent and pcDNA) (C). Quantitative analysis showed that the majority of the cells 
that were TUNEL(+) at 72 h were aneuploid, regardless of whether they were negative 
controls or were expressing wild-type or mutant MAPT (D). A representative apoptotic 
(green, from Reagent) cell with trisomy 12 at 72 h is shown (E); FISH for chromosomes 
12 and 21 (I), FISH and DAPI (II), NeuN staining (III) and merged imaged (IV). Analysis 
of the frequency of apoptosis among aneuploid cells and of aneuploidy among apoptotic 
cells at 72 h indicates that around 70-80% of apoptotic cells were aneuploid, but only 
around 15-30% of aneuploid cells were apoptotic in both negative control cells and in 
cells expressing wild-type or mutant MAPT (F). The graphs show mean differences 
between treatments using ANOVA with Dunnett t test (A) and post-hoc test (C, D, and F) 
and pcDNA3.1 as comparison group (one-tailed; effect size ŋ
2 = 0.60 for trisomy 21 and 
ŋ
2 = 0.58 for trisomy 12). On average, ~500 cells/slide and three slides/sample for each 
of three replicates were scored. Significance was calculated using independent t-test. 
Error bars indicate SEM. *, P < 0.05; **, P < 0.005; and ***, P < 0.0005. 
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Figure 7. Mitotic Spindle Defects Induced by Expression of MAPT Harboring 
FTLD-Causing Mutations in a Karyotypically Normal Human Cell Line  
The hTERT-HME1 cell line was transfected in the absence of vector (Reagent), with the 
pcDNA3.1 vector alone (pcDNA), or with the pcDNA3.1 vector harboring wild-type 
MAPT (WT-MAPT), MAPT with the P301L mutation (P301L), or MAPT with the V337M 
mutation (V337M), and microscopy images were taken during the metaphase and 
anaphase stages of mitosis at 48 h post-transfection; microtubules are shown in red, 
and DNA is shown in blue. Normal spindles: the chromosomes are aligned properly in 
metaphase and are also undergoing proper segregation in anaphase (A–C). Abnormal 
spindles: lagging chromosomes, the majority of the chromosomes are aligned properly 
but some remain unattached and unaligned (D, E); multiple centrosomes: more than 
two microtubule arrays are present during mitosis (F, G); and microtubule aggregate: 
the tubulin subunits do not polymerize properly but instead form a cluster inside the 
nucleus (H, I). Cells expressing the mutant MAPT genes (P301L or V337M) show a 
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significant increase in MT abnormalities in comparison to samples transfected with the 
pcDNA vector alone or in the absence of vector (J). The graphs show mean difference 
and significance (*) of the cells transfected with the mutant MAPT genes compared to 
the pcDNA3.1 vector alone (sham-control) using ANOVA with Tukey post hoc test. Error 
bars indicate SEM. *, P ≤ 0.05; **, P ≤ 0.005.  
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Figure 8. Proposed Theoretical Mechanistic Pathway of Aneuploidy and 
Apoptosis in FTLD-MAPT and Other Tauopathies 
Based on the evidence presented here, which show that mutant MAPT-induced 
aneuploidy and apoptosis require cell division, we hypothesize that the expression of 
mutant forms of MAPT in the cells of FTLD-MAPT patients (or in patients with other 
tauopathies) would induce mitotic spindle defects, which would in turn lead to the 
accumulation of aneuploid cells over time as a result of aberrant cell division. An 
increase in the aneuploidy cell population would not only place a heavy burden on the 
aneuploid cells to overcome the detrimental effects of altered gene dosage, but also 
rendering them more vulnerable and prone to undergoing apoptosis. 
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Table 1. Demographics of Familial MAPT FTLD Cases and Age-Matched Control 
Individuals Without Neurologic Disease 
 
Diagnosis MAPT Mutation Age (years) Sex 
FTLD P301L 52 M 
 P301L 62 M 
 N279K 51 F 
 E372G 58 M 
Controls WT 59 F 
 WT 61 M 
 WT 63 M 
 WT 63 M 
 WT 53 M 
 WT 79 M 
 WT 74 M 
